Skip Navigation



Annals of Oncology Advance Access published online on October 27, 2005
Annals of Oncology, doi:10.1093/annonc/mdj039
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/2/276    most recent
mdj039v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Krege, S.
Right arrow Articles by Ruebben, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krege, S.
Right arrow Articles by Ruebben, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received June 22, 2005
Revised September 8, 2005
Accepted September 12, 2005

original article

Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG)

S. Krege 1*, C. Boergermann 1, R. Baschek 1, A. Hinke 2, T. Pottek 3, S. Kliesch 4, K.-P. Dieckmann 5, P. Albers 6, B. Knutzen 7, S. Weinknecht 8, H.-J. Schmoll 9, J. Beyer 10, and H. Ruebben 1

1 University/Medical School, Urology, Essen, Germany
2 Wissenschaftlicher Service Pharma, Langenfeld, Germany
3 Bundeswehrkrankenhaus, Urology, Hamburg, Germany
4 University/Medical School, Urology, Muenster, Germany
5 Albertinenkrankenhaus, Urology, Hamburg, Germany
6 Staedtische Kliniken, Urology, Kassel, Germany
7 Klinikum der Stadt Schwenningen, Urology, Villingen/Schwenningen, Germany
8 Kliniken Essen-Mitte-Hyssens-Stift, Urology, Essen, Germany
9 University/Medical School, Medical Oncology, Halle, Germany
10 University/Medical School, Medical Oncology, Marburg, Germany

* To whom correspondence should be addressed.
S. Krege, E-mail: susanne.krege{at}uni-essen.de


  Abstract

Background: The aim was to investigate the use of single agent carboplatin in patients with seminoma stage IIA/B.

Patients and methods: In a prospective phase II trial, single agent carboplatin at a dose of AUC 7 mg·min/ml every 4 weeks for three cycles in stage IIA (n = 51) or four cycles in stage IIB (n = 57) was given to 108 patients with previously untreated seminoma stage IIA/B. Patients with residual masses of ≥3 cm were scheduled to receive secondary surgery.

Results: A complete response (CR) was achieved by 88/108 (81%) patients, 17/108 (16%) achieved a partial response (PR), two of 108 (2%) showed no change, and one patient progressed. In all patients with PR the residual disease was ≤3 cm; yet in two of 17 patients with PR, in two of two patients with NC and in one patient with disease progression residual tumor resection was performed demonstrating vital seminoma. Toxicity was acceptable with grades 3 and 4 myelosuppression, nausea and vomiting in less than 10% of patients each. After a median follow-up of 28 months (range 1-68 months) 14/108 (13%) patients relapsed, all after having achieved a CR. All relapses occurred in the retroperitoneum. One patient died from an unrelated cause. The overall failure rate was 19/108 patients (18%). The overall and disease specific survival was 99% and 100%, respectively.

Conclusions: Four cycles of single agent carboplatin AUC 7 do not safely eradicate retroperitoneal metastases in patients with stage IIA/B seminoma.

Keywords: chemotherapy; carboplatin; testicular seminoma stage IIA/B.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
X. Garcia-del-Muro, P. Maroto, J. Guma, J. Sastre, M. Lopez Brea, J. A. Arranz, N. Lainez, D. S. de Prado, J. Aparicio, J. M. Piulats, et al.
Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study
J. Clin. Oncol., November 20, 2008; 26(33): 5416 - 5421.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. de Wit and K. Fizazi
Controversies in the Management of Clinical Stage I Testis Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.